# Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

> **NCT06722599** · — · RECRUITING · sponsor: **Shu Wang** · enrollment: 171 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06722599
- **Lead sponsor:** Shu Wang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 171 (ESTIMATED)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06722599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06722599, "Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06722599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*